Preface

Since the discovery of the molecular structure of genes and the unveiling of the molecular basis of numerous human diseases, scientists have been fascinated with the possibility of treating certain diseases by transducing foreign DNA into the affected cells. Initially, it was proposed that the foreign DNA could either replace defective nonfunctional genes, or code for therapeutic proteins. This concept has evolved into the rapidly growing field of gene therapy.

Even though surgery, radiotherapy, and chemotherapy are widely available and routinely used for cancer treatment, these therapies fail to cure approximately 50 percent of cancer patients. Therefore, since it is a disease characterized by aberrant gene expression, cancer has been a target of gene therapy research since the inception of this treatment modality. Numerous cancer gene therapy strategies are currently being investigated, including gene replacement therapy, the regulation of gene expression to modulate immunological responses to tumors, the direct killing of tumor cells, and direct interference with tumor growth. In this context, gene transfer systems, tumor-specific expression vectors, and novel therapeutic genes have been extensively studied. All these strategies aim for the selective destruction of human malignant disease while circumventing the destruction of nonmalignant cells and tissues thereby minimizing toxicity to the patient.

Rapid progress in the field of cancer gene therapy, exemplified by the vast number of publications in this area, creates a challenging situation for scientists and clinicians who need to be cognizant of the most recent advances in gene transfer techniques. This volume of *Gene Therapy of Cancer: Methods and Protocols* in the *Methods in Molecular Medicine* series will provide researchers with a broad array of methods used to study cancer gene therapy in both the laboratory and clinical trials. Moreover, several chapters are included to provide short overviews of specialized gene therapy strategies for the treatment of particular malignancies.

*Gene Therapy of Cancer: Methods and Protocols* does not provide comprehensive reviews of all methodologies currently used for gene therapy of cancer. Rather the topics we have selected consist of approved procedures,
current trends, and representative strategies in cancer gene therapy using dif-
ferent classes of therapeutic genes, suppressor genes, antisense oligonucle-
otides, ribozymes, viral- and nonviral-vector systems, and tumor targeting
approaches at the preclinical and, more importantly, at the clinical level. For
cancer gene therapy to be successful in the treatment of human cancers, exten-
sive preclinical evaluation is essential. Therefore, the first part of this book
discusses relevant experiments from preclinical studies followed by clinical
gene therapy protocols in the second part.

*Gene Therapy of Cancer: Methods and Protocols* should provide practi-
cal guidance for basic and clinical researchers, as well as graduate and post-
graduate students working in the exciting and emerging field of gene therapy.

_Wolfgang Walther_

_Ulrike Stein_
Contributors

MANISH AGHI • Molecular Neurogenetics Unit, Massachusetts General Hospital East, Charlestown, MA
ANDREAS ALBERS • Centrum Somatische Gentherapie at Freie Universität Berlin, Berlin, Germany
RAMON ALEMANY • Wallace Tumor Institute, Department of Medicine–Pulmonary and Critical Care, University of Alabama, Birmingham, AL
K.-H. ALTMAN • Oncology Research, Novartis Pharma, Basel, Switzerland
DONALD D. ANTHONY • Department of Pharmacology, Case Western Reserve University, Cleveland, OH
DAVID BERMUDES • VION Pharmaceuticals, New Haven, CT
MASAMI BESSHO • First Department of Internal Medicine, Saitama Medical School, Saitama, Japan
GUADALUPE BILBAO • Gene Therapy Program, University of Alabama at Birmingham, Birmingham, AL
HANS BOJAR • Institut für Onkologische Chemie, Heinrich Heine Universität Düsseldorf, Düsseldorf, German
ROBERTA BONAGURO • Institute of Microbiology, University of Padova Medical School, Padova, Italy
KARSTEN BRAND • Max-Delbrück-Center for Molecular Medicine, Berlin, Germany
XANDRA O. BREAKEFIELD • Molecular Neurogenetics Unit, Massachusetts General Hospital East, Charlestown, MA
J. MARTIN BROWN • Cancer Biology Research Laboratories, Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA
PATRICIA A. BRUSO • Department of Head and Neck Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, TX
LING CHEN • Department of Human Genetics, Merck Research Laboratories, West Point, PA
GARY L. CLAYMAN • Department of Head and Neck Surgery, M.D. Anderson Cancer Center, University of Texas, Houston, TX
xii Contributors

FREDERICO COLOMBO • Institute of Microbiology, University of Padova Medical School, Padova, Italy
MARIO P. COLOMBO • Experimental Oncology Department, Istituto Nazionale Tumori, Milano, Italy
JUAN LUIS CONTRERAS • Gene Therapy Program, Lurleen B. Wallace Tumor Institute, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL
MATTHEW COOPERBERG • Genetic Therapy Program of the Yale Cancer Center, and the Medical Oncology Section, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT
DAVID T. CURIEL • Gene Therapy Program, University of Alabama at Birmingham, Birmingham, AL
ALBERT DEISSEROTH • Department of Internal Medicine, Yale University School of Medicine, New Haven, CT
DON DIZON • Genetic Therapy Program of the Yale Cancer Center and the Medical Oncology Section, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT
INGO DREXLER • Institut für Molekulare Medizin, Bavarian Nordic Research Institute, Neuherberg, Germany
VOLKER ERFLE • Institut für Molekulare Medizin, Bavarian Nordic Research Institute, Neuherberg, Germany
DORIANO FABBRO • Oncology Research, Novartis Pharma, Basel, Switzerland
FRANK FLOETH • Neurochirurgische Klinik, Heinrich Heine Universität Düsseldorf, Germany
MARY E. FOX • Division of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA
DOUGLAS K. FRANK • Department of Head and Neck Surgery, M.D. Anderson Cancer Center, University of Texas, Houston, TX
SCOTT M. FREEMAN • Clinical Research Oncology, Schering–Plough Research Institute, Kenilworth, NJ
SI QING FU • Genetic Therapy Program of the Yale Cancer Center and the Medical Oncology Section, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT
EVA NTHIA GALANIS • Division of Medical Oncology, Mayo Clinic, Rochester, MN
THOMAS GEIGER • Oncology Research, Novartis Pharma, Basel, Switzerland
AMATO J. GIACCIA • Cancer Biology Research Laboratories, Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA
JESUS GOMEZ-NAVARRO • Gene Therapy Program, University of Alabama at Birmingham, Birmingham, AL
WALTER GÜNZBURG • Institute of Virology, University of Veterinary Sciences, Vienna, Austria
XIANG YANG DAVID GUO • Genetic Therapy Program of the Yale Cancer Center and the Medical Oncology Section, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT
NAGY B. HABIB • Liver Surgery Section, Imperial College School of Medicine Hammersmith Hospital Campus, London, UK
JODI E. D. HECHT • Department of Biology, Boston University, Boston, MA
KARL HELLER • Institut für Molekulare Medizin, Bavarian Nordic Research Institute, Neuherberg, Germany
ULRICH HERRLINGER • Neurologische Universitätsklinik Tübingen, Tübingen, Germany
JEFFREY T. HOLT • Department of Cell Biology, Vanderbilt University, Nashville, TN
AKIO IDO • Second Department of Internal Medicine, Miyazaki Medical College, Miyazaki, Japan
ANDREAS JACOBS • Molecular Neurogenetics Unit, Massachusetts General Hospital East, Charlestown, MA
YOUSSEF JOUNAIDI • Department of Biology, Boston University, Boston, MA
KEIZO KAZANO • Gene Therapy Program, University of Alabama at Birmingham, Birmingham, AL
DAVID H. KIRN • Onyx Pharmaceuticals, Richmond, CA
HIROYUKI KOBAYASHI • Division of Neoplastic Diseases, Department of Medicine, Mount Sinai School of Medicine, New York, NY
WEN-HWA LEE • Department of Molecular Medicine, Institute of Biotechnology, The University of Texas Health Science Center, San Antonio, TX
MARILYN J. LEMMON • Cancer Biology Research Laboratories, Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA
NICHOLAS R. LEMOINE • Imperial Cancer Research Fund Oncology Group, Imperial College School of Medicine at Hammersmith, Hammersmith Hospital, London, UK
DEBBIE LIN • Genetic Therapy Program of the Yale Cancer Center and the Medical Oncology Section, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT
BROOKS LOW • Therapeutic Radiology, Yale University School of Medicine, New Haven, CT
Selina Luger • Bone Marrow Transplant Program, Division of Hematology and Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA

Katalin V. Lukacs • National Heart and Lung Institute, Imperial College, London, UK

Aizen J. Marrogi • Department of Surgery, Louisiana State University School of Medicine, New Orleans, LA

Nigel P. Minton • Centre for Applied Microbiology and Research, Porton Down, Salisbury, Wiltshire, UK

Ragai R. Mitry • Liver Surgery Section, Imperial College School of Medicine, Hammersmith Hospital Campus, London, UK

B. P. Monia • Department of Molecular Pharmacology, Carlsbad Research Center, ISIS Pharmaceuticals, Carlsbad, CA

Anupama Munshi • Department of Surgery, Louisiana State University School of Medicine, New Orleans, LA

Shigenobu Nagataki • Radiation Effects Research Foundation, Hiroshima, Japan

Artit Nakakes • National Heart and Lung Institute, Imperial College, London, UK

Thong Nanakorn • Genetic Therapy Program of the Yale Cancer Center and the Medical Oncology Section, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT

John Nemunaitis • Mary C. Crowley Cancer Research Program, Baylor Research Institute, Baylor University Medical Center, Dallas, TX

Patrice S. Obermiller • Department of Cell Biology, Vanderbilt University, Nashville, TN

Marion Ohlmann • Institut für Molekulare Medizin, Bavarian Nordic Research Institute, Neuherberg, Germany

Takao Ohnuma • Division of Neoplastic Diseases, Department of Medicine, Mount Sinai School of Medicine, New York, NY

Giorgio Palù • Institute of Microbiology, University of Padova Medical School, Padova, Italy

Yue Xin Pan • Department of Pharmacology, School of Medicine, Case Western Reserve University, Cleveland, OH

Hardev S. Pandha • Department of Medicine, Royal Marsden Hospital, Surrey, UK

John M. Pawelek • Departments of Dermatology and Pharmacology, Yale University School of Medicine, New Haven, CT

Lene Pedersen • Department of Molecular and Structural Biology, University of Aarhus, Aarhus, Denmark
Xue Yan Peng • Genetic Therapy Program of the Yale Cancer Center and the Medical Oncology Section, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT

Massimo Pizzato • Institute of Microbiology, University of Padova Medical School, Padova, Italy

Alexander L. Rakhmilevich • Department of Human Oncology, University of Wisconsin Medical School, Madison, WI

Rajagopal Ramesh • Department of Thoracic and Cardiovascular Surgery, M.D. Anderson Cancer Center, Houston, TX

Daniel J. Riley • Department of Medicine, Division of Nephrology, University of Texas Health Center, San Antonio, TX

Monica Rodolfo • Department of Experimental Oncology, Istituto Nazionale Tumori, Milano, Italy

Joseph Rubin • Division of Medical Oncology, Mayo Clinic, Rochester, MN

Volker Sandig • Max-Delbrück-Center for Molecular Medicine, Berlin, Germany

Kevin J. Scanlon • Berlex Biosciences, Richmond, CA

Dirk Schadendorf • Clinical Cooperation Unit for Dermatology at the Department of Dermatology Clinics, Mannheim Universität Heidelberg, Mannheim, Germany

Pamela Schreiber Schwartz • Department of Biology, Boston University, Boston, MA

Peter M. Schlage • Departments of Surgery and Surgical Oncology, Robert-Rössle-Clinic, Charité at the Humboldt University, Berlin Germany

Deborah E. Schuback • Molecular Neurogenetics Unit, Massachusetts General Hospital East, Charlestown, MA

Robert H. Shoemaker • Antiviral Evaluations Branch, Developmental Therapeutics Program, National Cancer Institute, Rockville, MD

Shrinivasan Shrimkandana • Genetic Therapy Program of the Yale Cancer Center and the Medical Oncology Section, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT

Kyonghee Kay Son • Department of Pharmaceutics, College of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ

Ulrike Stein • Max-Delbrück-Center of Molecular Medicine, Robert-Rössle Strasse, Berlin, Germany

Wolfram Sterry • Department of Dermatology Charité, Humboldt University Berlin, Berlin, Germany

Michael Strauss • Max-Delbrück-Center for Molecular Medicine, Berlin, Germany

Gerd Sutter • Institut für Molkulare Medizin, Bavarian Nordic Research Institute, Neuherberg, Germany